Read more from the company presentation here.
-----
And as I mentioned previously, NMTC has 5 must-see potential catalysts right now:
No. 1 NMTC Potential Catalyst - A Low Float Provides Volatility Potential Daily
According to the Yahoo Finance website, NMTC has a low float.
The website reports this profile to have approximately 14.91Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive 2023 company news help provide a near term spark?
-----
No. 2 NMTC Potential Catalyst - Company Submits 510(k) Application To FDA For OneRF™ Ablation System
NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System
Potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the added benefit of temperature control
EDEN PRAIRIE, Minn., June 12, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today its submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for its OneRF™ Ablation System. This technology uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary radio frequency (RF) generator. If cleared by the FDA, NeuroOne’s OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery.
As the Company’s first therapeutic device, OneRF is a combination system that includes both diagnostic and therapeutic capabilities. The system utilizes a customized RF generator with real-time temperature monitoring capabilities, allowing clinicians to have greater control over temperature management during the ablation. Designed to both record brain activity and ablate nervous tissue using the same electrode, the system is designed to offer the potential for a safer clinical option for patients as well as lower costs by reducing the number of invasive procedures and hospital stays for patients. NeuroOne estimates the current brain ablation market to be at least $100Mn worldwide and growing rapidly, with the potential to grow multiple fold based on large addressable patient populations with unmet clinical needs.
Dave Rosa, CEO of NeuroOne, commented, “This is a monumental day for NeuroOne as it represents the first known FDA 510(k) submission of an sEEG electrode intended to record brain activity and also be used as an RF probe to ablate nervous tissue. In addition, it marks the Company’s first complete system combining hardware, software, and our novel electrode technology. Over the past few years, we have been excited with the feedback we have received from our advisory board as well as the performance of the system in animal feasibility studies. We also believe this system has applications beyond ablation of nervous tissue in the brain, offering a larger opp. than we initially envisioned. I am proud of our entire team and their efforts which allowed us to complete this before the end of June as planned.”
NeuroOne anticipates receiving initial feedback from the FDA no later than August 7th, 2023.
Read the full article here.
-----
No. 3 NMTC Potential Catalyst - Company Creates New Potential Revenue Stream With Key U.S. Commercial Launch
NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes
Evo sEEGs complementary to Zimmer Biomet’s robotic neurosurgery platform; strong market opp. for paired technologies
EDEN PRAIRIE, Minn., May 02, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the commercial launch of the Evo® sEEG electrode product line in the United States. Zimmer Biomet holds exclusive worldwide distribution rights to NeuroOne’s Evo Cortical and sEEG product lines, and the Evo product line is expected to utilize Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures.
Dave Rosa, CEO of NeuroOne, commented, “The commercial launch of the Evo sEEG platform represents one of the most impactful milestones in our Company’s history. Paired with Zimmer Biomet’s ROSA One Brain robotic platform and broad distribution network, we believe the Company is well positioned in the market given the synergies that exist between our novel thin film electrode platform and Zimmer Biomet’s robotic platform. Importantly, this new technology potentially provides NeuroOne with a steady and predictable new revenue stream. We expect to complete our initial case within the next 30 days.”
...
NeuroOne’s Evo sEEG electrode technology offers stereoelectroencephalography recording, brain stimulation and future capabilities for spinal cord stimulation, and ablation solutions targeted for patients suffering from epilepsy, chronic back pain, and Parkinson’s disease. The Evo® sEEG is the Company’s most advanced diagnostic electrode designed to be secure, precise, and less invasive, with proven placement accuracy and signal quality, and made in a mostly automated manufacturing process.
In October 2022, NeuroOne received FDA clearance to market its Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.
Read the full article here.
-----
No. 4 NMTC Potential Catalyst - Milestone "Firsts" For The Company's Game-Changing Evo® sEEG Electrode
In recent months, the company has made a few milestone announcements in regards to firsts for the Evo® sEEG Electrode being put to use.
Here's what you need to know:
NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery
Evo sEEG electrode used with Zimmer Biomet’s ROSA One® Brain during procedure at Cleveland Clinic
EDEN PRAIRIE, Minn., May 17, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo® sEEG electrode in robotic neurosurgery. Performed by Dr. William Bingaman at Cleveland Clinic, the procedure was the first to utilize NeuroOne’s Evo sEEG electrode, exclusively marketed in the U.S. by Zimmer Biomet, with Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures.
Dave Rosa, CEO of NeuroOne, commented, “This clinical case utilizing our minimally invasive and high-definition electrode technology with ROSA One Brain is a major milestone in NeuroOne’s partnership with Zimmer Biomet. Now that Zimmer Biomet has commenced U.S. distribution of our Evo sEEG electrodes, this case study confirms the synergistic use of our product with Zimmer Biomet’s robotics platform which was the foundation of our interest to partner with Zimmer Biomet.”
...
Read the full article here.
And just prior to that announcement:
NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic
Evo sEEG electrodes used for brain mapping in epilepsy surgery
EDEN PRAIRIE, Minn., May 10, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its first clinical case using the Evo® sEEG electrode was performed by Dr. Jamie Van Gompel at Mayo Clinic. Using a non-robotic stereotactic frame system, Evo electrodes were implanted successfully and met the Company’s product performance objectives.
Dave Rosa, CEO of NeuroOne, commented, “We would like to thank Dr. Van Gompel and his surgical team at Mayo for this 'first in the world' opp. We are ecstatic with the initial performance of our Evo sEEG electrodes which confirmed the results of many years of testing on the device. While we previously used the device intraoperatively, this was the first clinical case that was cleared by the FDA for less than 30 day use. We look forward to continued success with the launch of the technology as we continue the roll out of the technology through our distribution partner, Zimmer Biomet.”
...
Read the full article here.
-----
No. 5 NMTC Potential Catalyst - Exciting Patent News Adds To Company's Growing Portfolio
NeuroOne® Awarded U.S. Patent Covering Novel and Proprietary Thin Film Electrode Platform
New patent adds value to NeuroOne's growing patent portfolio in the U.S. and abroad
EDEN PRAIRIE, Minn., March 7, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces it has been awarded a patent from the United States Patent and Trademark Office relating to its novel and proprietary electrode technology.
The patent, titled "Improved Neural Depth Probes and Related Systems and Methods," adds to NeuroOne's intellectual property portfolio, and is focused on a layered thin film neural depth electrode. The electrode could have potential applications in a wide variety of neurological procedures for both diagnostic and therapeutic use. Conditions that could potentially benefit from this technology include epilepsy, Parkinson's disease, chronic back pain due to failed back surgeries, and mood- based disorders associated with depression, severe OCD, etc.
In addition to this patent, NeuroOne's patent portfolio includes three licensed patents, eight pending U.S. applications, and several foreign applications covering a wide variety of thin-film electrode technologies, including both neural and spinal cord electrodes having unique properties to optimize the functionality and minimized profile of those electrodes, enabling less invasive surgeries. More specifically, the inventions described in the patent applications include electrodes and related devices with drug delivery capabilities, spinal cord stimulation electrodes, ablation electrodes, and electrodes with temperature sensing features.
Dave Rosa, CEO of NeuroOne, comments, "NeuroOne is committed to protecting our groundbreaking electrode technology with respect to device claims and proprietary manufacturing processes. With a plethora of patent applications both in the U.S. and overseas relating to procedures in epilepsy, Parkinson's disease, chronic back pain and drug/gene delivery, we believe the Company is well positioned to impact a number of key neurological conditions with patent-protected novel electrodes. We look forward to continued success with our patent applications."
Read the full article here.
-----
NMTC Recap: 5 Potential Breakout Catalysts To Know Immediately
No. 1 - A Low Float Provides Volatility Potential Daily
No. 2 - Company Submits 510(k) Application To FDA For OneRF™ Ablation System
No. 3 - Company Creates New Potential Revenue Stream With Key U.S. Commercial Launch
No. 4 - Milestone "Firsts" For The Company's Game-Changing Evo® sEEG Electrode
No. 5 - Exciting Patent News Adds To Company's Growing Portfolio
-----
Coverage is officially reinitiated on NMTC. When time permits, do this:
